{"title":"Bacterial keratitis in patients with corneal lesions in southeastern Iran: microbial spectrum, demographic characteristics, and seasonal distribution.","authors":"Mehdi Zarean, Ghodratollah Salehi Sangani, Mahsa Khodkari, Mojtaba Mousavi Bazaz, Soudabeh Etemadi","doi":"10.1186/s40794-026-00322-2","DOIUrl":"10.1186/s40794-026-00322-2","url":null,"abstract":"<p><strong>Background and objective: </strong>Bacterial keratitis is a sight-threatening ophthalmic emergency that can rapidly progress to corneal ulceration, perforation, endophthalmitis, and permanent blindness if inappropriately managed. Despite its clinical significance, there is a paucity of comprehensive regional microbiological surveillance data regarding the microbial etiology of bacterial keratitis in southeastern Iran. Therefore, this study aimed to provide an updated regional microbiological surveillance report, detailing the bacterial profile, seasonal distribution, and demographic patterns of bacterial keratitis in patients presenting with corneal lesions in this area.</p><p><strong>Materials and methods: </strong>This retrospective, descriptive cross-sectional study was conducted between 2020 and 2025. Data were retrieved from the medical registries of tertiary teaching hospitals affiliated with Zahedan University of Medical Sciences. Demographic variables (age, sex), seasonal onset, and microbiological isolates were extracted using standardized checklists. Patients with incomplete clinical or laboratory records were excluded. As a descriptive surveillance study, data were analyzed to establish local epidemiological baselines and pathogen distributions. Statistical analysis was performed using SPSS version 26.</p><p><strong>Results: </strong>A total of 358 patients were evaluated, comprising 217 males (60.6%) and 141 females (39.4%). While bacterial isolates showed numerical variations across seasons (higher in Spring/Summer: 52.0% vs. Autumn/Winter: 48.0%) and genders (males: 60.6%), these demographic and seasonal distributions were not statistically significant (p > 0.05p > 0.05). The five most prevalent bacterial isolates were Staphylococcus epidermidis (n = 126, 35.2%), Staphylococcus saprophyticus (n = 59, 16.5%), Streptococcus pneumoniae (n = 50, 14.0%), Pseudomonas spp. (n = 37, 10.3%), and Acinetobacter spp. (n = 23, 6.4%). Regarding age distribution, S. epidermidis was most frequent in patients aged ≤ 20 years (n = 40) and ≥ 61 years (n = 37), whereas S. saprophyticus peaked in the ≤ 20 years age group (n = 27). Furthermore, Streptococcus pneumoniae (n = 23), Pseudomonas spp. (n = 15), and Acinetobacter spp. (n = 10) showed higher frequencies in older adults aged ≥ 61 years. Temporally, peak numerical frequencies of S. epidermidis, S. saprophyticus, and Acinetobacter spp. occurred in summer, while S. pneumoniae and Pseudomonas spp. peaked in autumn. All major isolates exhibited a higher numerical frequency in male patients.</p><p><strong>Conclusion: </strong>Bacterial keratitis in southeastern Iran is characterized by a predominance of Gram-positive cocci, with Staphylococcus epidermidis being the most common isolate. Although numerical variations across seasons and genders were observed, they lacked statistical significance. Consequently, empirical therapy and clinical management should remain consistent throughout the yea","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evidence of dengue virus exposure among Iranian seafarers: a brief seroprevalence report from Southern Iran.","authors":"Amirhossein Darabi, Mahboobeh Hayati, Golnaz Hayatdavoudi, Omid Gharibi, Sahand Khajeheian, Mohsen Keshavarz","doi":"10.1186/s40794-026-00323-1","DOIUrl":"10.1186/s40794-026-00323-1","url":null,"abstract":"<p><strong>Introduction: </strong>Dengue virus (DENV) is an emerging public health concern in Iran. Frequent maritime travel between southern Iranian ports and neighboring countries with reported dengue transmission may facilitate the introduction of DENV into Iran. Therefore, this study aimed to determine the seroprevalence of DENV among Iranian seafarers.</p><p><strong>Methods: </strong>We conducted a cross-sectional serosurvey among 270 seafarers in Bushehr Province. Serum samples were tested for DENV IgM/IgG using ELISA. Travel history and demographics were collected via questionnaires.</p><p><strong>Results: </strong>Serological testing identified 7 DENV-seropositive individuals (2.6%), including 2 IgM-positive and 5 IgG-positive participants. Seropositivity was higher among recent travelers than among past travelers (5.6% vs. 1.5%). Positive cases were detected in Bushehr (5.0%), Asaluyeh (16.7%), Genaveh (5.0%), Kangan (1.7%), and Dayyer (1.3%), whereas no seropositive cases were identified among participants employed in Deylam.</p><p><strong>Conclusions: </strong>Although DENV seroprevalence remained low among Iranian seafarers, evidence of both recent and past infections indicates that occupational maritime travel may contribute to DENV exposure. Given the strategic role of seafarers in cross-border movement, periodic serological surveillance of this occupational group may facilitate early detection of DENV introduction and strengthen public health preparedness in southern Iran.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlie Franck Amoia, Gerald Misinzo, Muhammad Munir
{"title":"Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.","authors":"Charlie Franck Amoia, Gerald Misinzo, Muhammad Munir","doi":"10.1186/s40794-026-00320-4","DOIUrl":"10.1186/s40794-026-00320-4","url":null,"abstract":"<p><p>Newcastle disease virus (NDV) remains one of the most economically devastating pathogens affecting poultry production. Despite decades of vaccination efforts, NDV continues to circulate and remain endemic across Asia, Africa, and the Middle East, posing persistent threats to food security, rural livelihoods, and international trade. This review comprehensively examines the current landscape of NDV vaccine platforms, their immunological mechanisms, and the multifaceted challenges limiting their efficacy. We critically evaluated conventional platforms, including lentogenic live attenuated vaccines and oil-adjuvanted inactivated formulations, highlighting their contributions to disease control while addressing their inherent limitations including cold-chain dependence, maternal antibody interference, incomplete cross-protection against heterologous genotypes, and the absence of differentiating infected from vaccinated animals (DIVA) capability. We then examined next-generation approaches, including recombinant vector platforms, virus-like particles, DNA and mRNA vaccines, and AI/ML-informed antigen design, assessing each against its actual stage of development, from vaccines already in commercial use to platforms that remain preclinical or theoretical, rather than treating design capability as equivalent to field-ready deployment. Finally, we addressed regulatory, manufacturing, and logistical barriers to vaccine deployment in low-resource settings, including a dedicated feasibility assessment and platform-comparison table for smallholder-dominated, endemic regions. Integrating these technological advances with robust surveillance, biosecurity, and supportive policies will be essential for achieving sustainable NDV control and advancing toward eradication.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Danique J H Huijbens, Martijn Tilanus, Radjin Steingrover, Juldany Juliet, Marquita Euson, Sharda Baboe-Kalpoe, Fazal Baboe, Shanna Holaman, Sherryl Carty-Fleming, Felix Holiday, Chérina Fleming, Sheryl Etienne-Leblanc, Joseph Isaac, Carshena Gordon, Sam Engels, Marien I de Jonge, Lilly M Verhagen, Josephine S van de Maat
{"title":"Saharan dust exposure triggers or exacerbates existing respiratory morbidity in the Caribbean - an observational study.","authors":"Danique J H Huijbens, Martijn Tilanus, Radjin Steingrover, Juldany Juliet, Marquita Euson, Sharda Baboe-Kalpoe, Fazal Baboe, Shanna Holaman, Sherryl Carty-Fleming, Felix Holiday, Chérina Fleming, Sheryl Etienne-Leblanc, Joseph Isaac, Carshena Gordon, Sam Engels, Marien I de Jonge, Lilly M Verhagen, Josephine S van de Maat","doi":"10.1186/s40794-026-00319-x","DOIUrl":"10.1186/s40794-026-00319-x","url":null,"abstract":"<p><p>We evaluated the impact of Saharan dust on paediatric hospital admissions due to respiratory tract infections (RTIs) at St. Maarten. This study shows more RTI admissions after Saharan dust presence, with the strongest effect at 3 days after exposure (OR 1.5, 95%CI 1.2-2.0). This highlights the impact of air quality on respiratory health and the need for preventive measures, especially for vulnerable populations who intend to travel to Saharan dust-prone regions.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cavin Epie Bekolo, Nina Ngouenko, Esther Laura Nyame Dipepa Nwall, Leonard Ewane
{"title":"Assessing the impact of routine malaria vaccination on total disease burden in Cameroon: a nationwide difference‑in‑differences analysis using health district surveillance data (2023-2025).","authors":"Cavin Epie Bekolo, Nina Ngouenko, Esther Laura Nyame Dipepa Nwall, Leonard Ewane","doi":"10.1186/s40794-026-00318-y","DOIUrl":"https://doi.org/10.1186/s40794-026-00318-y","url":null,"abstract":"<p><strong>Background: </strong>Cameroon introduced the RTS, S/AS01 malaria vaccine into routine expanded immunisation (EPI) in 2024, targeting 42 priority health districts. We assessed changes in total malaria burden between intervention and non-intervention districts over 2023-2025.</p><p><strong>Methods: </strong>We conducted a retrospective, quasi-experimental, ecological longitudinal study using a difference-in-differences (DiD) approach on routine district-level surveillance data from 206 districts (42 intervention, 164 non-intervention) for 2023-2025. Outcomes included severe malaria rate (per 1,000 children < 5), uncomplicated malaria rate, all malaria-related hospitalisations, and malaria mortality rate (per 100,000). Crude pre-post changes and DiD were calculated. Adjusted linear DiD models with district and year fixed effects and cluster-robust standard errors were also fitted. Subgroup analyses examined interactions with seasonal malaria chemoprevention (SMC), intermittent preventive treatment in infants (IPTi), insecticide-treated nets (ITNs), and ecological region.</p><p><strong>Results: </strong>Baseline characteristics differed significantly: intervention districts had higher ITN coverage (60.2% vs. 45.5%, p = 0.006), higher IPT coverage (35.1% vs. 24.4%, p = 0.001), and larger populations (median 121,284 vs. 89,592, p = 0.029). From 2023 to 2025, intervention districts experienced larger declines in all outcomes. Crude DiD showed a 2.6 per 1000 (15%) reduction in severe malaria, 8.1 per 1000 (22%) reduction in uncomplicated malaria, 5.3 per 1000 (28%) reduction in hospitalisations, and 4.1 per 100,000 (26%) reduction in malaria deaths. Adjusted linear DiD estimates were not statistically significant (e.g., severe malaria coefficient - 0.54, 95% CI - 11.07 to 9.99, p = 0.920). Subgroup analyses indicated the largest effects in the Sahel (crude rate ratio 0.78) and added benefit when the vaccine was combined with SMC (additional - 5.6 per 1000 reduction). In 2025 alone, vaccination averted an estimated 7,200 severe cases, 12,800 uncomplicated cases, 5,300 hospitalisations, and 77 deaths.</p><p><strong>Conclusion: </strong>Crude trends show favourable declines in malaria burden in intervention districts, but adjusted estimates were null, likely due to selection bias and low power. These findings support continued vaccine scale-up and use of routine data for monitoring, while acknowledging the limitations of non-randomised evaluations.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Travel vaccination in senior travelers: current evidence, challenges, and prevention.","authors":"Andrea Rossanese, Alberto Tomasi","doi":"10.1186/s40794-026-00315-1","DOIUrl":"10.1186/s40794-026-00315-1","url":null,"abstract":"<p><p>The substantial number of older adults undertaking international travel has increased the relevance of pre-travel prevention in this population. However, vaccination strategies in this group require consideration of immune aging, baseline status, medication use, and travel-related exposure. This narrative review summarizes the current evidence on vaccination in senior travelers, with particular attention to the vaccines most relevant to this population, the differences in the strength of evidence across vaccines, and the clinical factors that should guide pre-travel decision-making. Routine vaccines, including influenza, COVID-19, pneumococcal, respiratory syncytial virus, herpes zoster, and tetanus-diphtheria vaccines, constitute an essential part of pre-travel assessment, whereas travel-specific vaccines, such as hepatitis A, hepatitis B, typhoid, rabies, Japanese encephalitis, tick-borne encephalitis, and cholera, should be considered according to the destination, itinerary, expected exposure, and time before departure. Yellow fever vaccination represents a particular clinical challenge because advancing age is associated with a greater risk of serious vaccine-associated adverse events, making individualized risk‒benefit assessment essential. Recently introduced dengue and chikungunya vaccines should also be considered on an individualized basis, taking into account exposure risk, potential benefits, comorbidities, and the current limitations of the available evidence. The review also highlights the importance of integrating vaccination with non-vaccine preventive strategies, including food and water precautions, vector avoidance, and hygiene measures. Although the evidence base has expanded, important uncertainties remain, particularly because age-specific data are limited and frail older adults remain underrepresented in clinical studies. Overall, pre-travel care for senior travelers should be comprehensive, exposure-based, and individualized according to the clinical profile and travel characteristics of each traveler.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison of viral respiratory pathogens circulation among Iranian pilgrims during two large religious mass gatherings: the Hajj and Arbaeen walk 2025.","authors":"Akram Sadat Ahmadi, Sevrin Zadheidar, Tasnim Jamalvandi, Fatemeh Saadatmand, Nazanin Zahra Shafiei-Jandaghi, Ghobad Moradi, Mahshid Nasehi, Jila Yavarian","doi":"10.1186/s40794-026-00317-z","DOIUrl":"10.1186/s40794-026-00317-z","url":null,"abstract":"<p><strong>Background: </strong>The Hajj and Arbaeen walk pilgrimages are significant religious mass gatherings (MGs) among Muslims. Respiratory tract infections (RTIs) remain a major concern during such events. This study aimed to evaluate the prevalence of respiratory viral infections among Iranian pilgrims during the 2025 Hajj and Arbaeen walk.</p><p><strong>Methods: </strong>Throat swabs were collected from 110 symptomatic Iranian pilgrims returning from these MGs. Molecular techniques were used to detect respiratory viruses.</p><p><strong>Results: </strong>A total of 60 Hajj pilgrims and 50 Arbaeen walk pilgrims, with an age range 8 to 82 years for the combined groups, participated. Rhinovirus was the most common virus detected among symptomatic pilgrims in both MGs. Notably, the rate of SARS-CoV-2 infection was 1.7% in Hajj pilgrims and 32% in Arbaeen pilgrims. Co-infections of rhinovirus and SARS-CoV-2 were identified in 8% of Arbaeen pilgrims. Additionally, coronavirus OC43/HKU1, influenza A (H3N2), and influenza B virus were detected at low frequencies. No cases of MERS-CoV were found among the 2025 Hajj pilgrims.</p><p><strong>Conclusion: </strong>These findings provide preliminary data on the circulation of respiratory viruses during religious MGs in 2025. Continued surveillance is essential to reduce respiratory infection risks during such mass gatherings.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.","authors":"Omid Salahi Ardekani, Parisa Hasannezhad, Yasaman Goudarzi, Arash Letafati, Zahra Taghiabadi, Mahshid Bahari, Negar Nayerain Jazi, Ali Qaraee Najafabadi, Somayeh Shatizadeh Malekshahi","doi":"10.1186/s40794-026-00313-3","DOIUrl":"10.1186/s40794-026-00313-3","url":null,"abstract":"<p><p>Respiratory Syncytial Virus (RSV) is a formidable respiratory pathogen that particularly affects infants and children. RSV presents with diverse clinical severity, most often causing mild upper airway symptoms but sometimes progressing to severe and potentially fatal lower respiratory tract disease. This virus has a major global public health impact and places a substantial strain on healthcare systems. RSV exhibits distinct seasonal trends that vary across geographic locations and climate zones, and recognizing these patterns and their determinants is essential for policymakers to schedule RSV immunization programs effectively. Increasing attention has been directed toward the evolving landscape of RSV vaccines, particularly regarding their potential to prevent infection and reduce disease severity, especially among vulnerable populations. Until now, three RSV vaccines, Arexvy, Abrysvo, and mRESVIA, have received approval from the FDA. In addition, monoclonal antibodies such as Nirsevimab and Clesrovimab prevent severe RSV disease and are recommended for infants. Given the significant global impact of RSV, this narrative review addresses its multifaceted aspects, including epidemiology and global impact, clinical manifestations, therapeutic strategies, vaccine development, and its emerging potential as an oncolytic agent.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aman Dev Singh, Simmi Oberoi, Kanwardeep Singh, Simranpreet Kaur, Monika Garg, Rajni Bassi, Amandeep Kaur, Kartik Attri, Shefali Gajebasia
{"title":"Rabies viral RNA and antibody response after post-exposure prophylaxis: Implications for blood donor deferral.","authors":"Aman Dev Singh, Simmi Oberoi, Kanwardeep Singh, Simranpreet Kaur, Monika Garg, Rajni Bassi, Amandeep Kaur, Kartik Attri, Shefali Gajebasia","doi":"10.1186/s40794-026-00312-4","DOIUrl":"10.1186/s40794-026-00312-4","url":null,"abstract":"<p><strong>Background: </strong>Rabies post-exposure prophylaxis (PEP) using anti-rabies vaccine and immunoglobulin is widely recognized as highly effective. However, individuals who receive PEP are typically deferred from blood donation for a full year, largely due to theoretical concerns about transfusion safety. However, the evidence supporting such a prolonged deferral remains limited.</p><p><strong>Objectives: </strong>This study aimed to assess rabies real-time RT-PCR status and serological responses among PEP recipients at various intervals following treatment and to consider whether these findings might justify a re-examination of the current one-year blood donor deferral policy after anti-rabies treatment.</p><p><strong>Methods: </strong>We conducted a single-center interventional study at an anti-rabies clinic in a tertiary hospital in North India. The study enrolled twenty immunologically naïve adults who had sustained category III animal bites, with no prior rabies exposure or treatment, and who adhered fully to the protocol. Participants received anti-rabies vaccines and equine rabies immunoglobulin as appropriate for their category. Follow-up samples were collected between as early as 48 days and 120 days after the bites. These samples were tested for rabies viral RNA using real-time RT-PCR (Geno-Sens Rabies Real-Time PCR Kit), and antibody titers were measured using ELISA (Rabies Platelia Kit II). Data analysis included descriptive statistics, percentile analysis, correlation analysis, and regression analysis, as appropriate.</p><p><strong>Results: </strong>In this cohort, dogs were responsible for 90% of bites, with 85% of incidents being unprovoked and 65% involving lower limbs. All participants tested negative using RT-PCR. ELISA titers ranged from 0.881 to 4.449 IU/mL, and all participants exceeded the protective threshold of 0.5 IU/mL. The mean titer was 2.97 ± 1.04 IU/mL.</p><p><strong>Conclusion: </strong>The lack of detectable rabies viral RNA, together with sustained protective antibody titers, indicates an effective response to PEP in this group. These findings support a more evidence-based reconsideration of the current prolonged blood donor deferral following anti-rabies treatment.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha Umaru Bai-Sesay, Daniel Lavalie, Mohamed S Bah, Patrick Maada Bundu, Aloubi Walter Emaka, Chizaram Anselm Onyeaghala
{"title":"Reframing pandemic preparedness: an intelligence-led solidarity model for multi-layered emergencies.","authors":"Alpha Umaru Bai-Sesay, Daniel Lavalie, Mohamed S Bah, Patrick Maada Bundu, Aloubi Walter Emaka, Chizaram Anselm Onyeaghala","doi":"10.1186/s40794-026-00310-6","DOIUrl":"10.1186/s40794-026-00310-6","url":null,"abstract":"<p><p>The convergence of infectious disease outbreaks, climate shocks, and conflict is exposing fundamental limitations in existing global health preparedness systems, which remain largely fragmented and disease-specific. Epidemics increasingly occur within multi-layered emergencies, where overlapping risks interact to overwhelm fragile health systems and complicate response efforts. This perspective examines structural gaps in current preparedness approaches, including siloed financing, limited integration of multi-sectoral intelligence, and constrained institutional autonomy. Drawing on a structured policy analysis of publicly available literature and institutional experiences, particularly from the Africa Centres for Disease Control and Prevention (Africa CDC), the analysis highlights how integrated epidemic intelligence and regional coordination can support more anticipatory and context-responsive preparedness. Africa CDC's evolving architecture illustrates the potential of combining surveillance data across health, environmental, and mobility domains to inform earlier and more targeted interventions. Building on these insights, this perspective proposes an intelligence-led solidarity model that integrates equitable resource allocation, interoperable regional intelligence, and predictable financing as interdependent components of resilient preparedness systems. Such an approach repositions preparedness as a shared global public good, emphasizing alignment between data, resources, and governance structures. In the context of increasingly complex and concurrent crises, an intelligence-led solidarity framework offers a pathway to strengthen global health security by enabling more coordinated, adaptive, and forward-looking responses.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13430818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}